SM-Youtube

1

Structural insights into the role and targeting of EGFRvIII.

Bagchi A, Stayrook SE, Xenaki KT, Starbird CA, Doulkeridou S, El Khoulati R, Roovers RC, Schmitz KR, van Bergen En Henegouwen PMP, Ferguson KM. Bagchi A, et al. Among authors: van bergen en henegouwen pmp. Structure. 2024 Jun 19:S0969-2126(24)00195-3. doi: 10.1016/j.str.2024.05.018. Online ahead of print. Structure. 2024. PMID: 38908376

2

Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains.

Schmitz KR, Bagchi A, Roovers RC, van Bergen en Henegouwen PM, Ferguson KM. Schmitz KR, et al. Structure. 2013 Jul 2;21(7):1214-24. doi: 10.1016/j.str.2013.05.008. Epub 2013 Jun 20. Structure. 2013. PMID: 23791944 Free PMC article.

3

Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy.

Mashayekhi V, Xenaki KT, van Bergen En Henegouwen PMP, Oliveira S. Mashayekhi V, et al. Among authors: van bergen en henegouwen pmp. Cancers (Basel). 2020 Sep 23;12(10):2732. doi: 10.3390/cancers12102732. Cancers (Basel). 2020. PMID: 32977602 Free PMC article.

4

Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.

Zeronian MR, Doulkeridou S, van Bergen En Henegouwen PMP, Janssen BJC. Zeronian MR, et al. Among authors: van bergen en henegouwen pmp. BMC Mol Cell Biol. 2022 Mar 1;23(1):12. doi: 10.1186/s12860-022-00412-x. BMC Mol Cell Biol. 2022. PMID: 35232398 Free PMC article.

5

A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.

Roovers RC, Vosjan MJ, Laeremans T, el Khoulati R, de Bruin RC, Ferguson KM, Verkleij AJ, van Dongen GA, van Bergen en Henegouwen PM. Roovers RC, et al. Int J Cancer. 2011 Oct 15;129(8):2013-24. doi: 10.1002/ijc.26145. Epub 2011 Aug 8. Int J Cancer. 2011. PMID: 21520037 Free PMC article.

6

Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.

Xenaki KT, Dorrestijn B, Muns JA, Adamzek K, Doulkeridou S, Houthoff H, Oliveira S, van Bergen En Henegouwen PM. Xenaki KT, et al. Theranostics. 2021 Mar 13;11(11):5525-5538. doi: 10.7150/thno.57510. eCollection 2021. Theranostics. 2021. PMID: 33859761 Free PMC article.

7

Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors.

Xenaki KT, Oliveira S, van Bergen En Henegouwen PMP. Xenaki KT, et al. Among authors: van bergen en henegouwen pmp. Front Immunol. 2017 Oct 12;8:1287. doi: 10.3389/fimmu.2017.01287. eCollection 2017. Front Immunol. 2017. PMID: 29075266 Free PMC article.

8

Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.

Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, de Haard HJ, van Bergen en Henegouwen PM. Roovers RC, et al. Cancer Immunol Immunother. 2007 Mar;56(3):303-317. doi: 10.1007/s00262-006-0180-4. Cancer Immunol Immunother. 2007. PMID: 16738850 Free PMC article.

9

Nanobodies in therapeutic applications.

Roovers RC, van Dongen GA, van Bergen en Henegouwen PM. Roovers RC, et al. Curr Opin Mol Ther. 2007 Aug;9(4):327-35. Curr Opin Mol Ther. 2007. PMID: 17694445 Review.

10

Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.

van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM, Roovers RC. van der Veeken J, et al. Curr Cancer Drug Targets. 2009 Sep;9(6):748-60. doi: 10.2174/156800909789271495. Curr Cancer Drug Targets. 2009. PMID: 19754359 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

120 results

Search Page

Filters

My NCBI Filters

Search Results

120 results